## **PRESS RELEASE**

Stockholm, Sweden, 31 August 2016



## New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

The total number of shares in <u>Swedish Orphan Biovitrum AB (publ)</u> (Sobi) as per 31 August 2016 amounts to 272,010,948 shares, whereof 270,389,770 common shares and 1,621,178 class C shares, corresponding to in total 270,551,887.8 votes. The increase in the number of shares and votes results from an issue of 188,142 class C shares under Sobi's incentive programme. The class C shares are intended to ensure fulfilment of commitments under incentive programmes. The company holds 1,640,735 common shares and all 1,621,178 class C shares.

---

## About Sobi™

Sobi™ is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm.

## For more information please contact

Media relations
Charlotte af Klercker, Sr Communications Manager
T: +46-707-297 327
charlotte.afklercker@sobi.com

Investor relations
Jörgen Winroth, Vice President, Head of Investor Relations
T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
jorgen.winroth@sobi.com

The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on 31 August 2016 at 08:00 CET.